SG11202101905YA - Vitamin d pediatric dosage forms, methods of making and using - Google Patents
Vitamin d pediatric dosage forms, methods of making and usingInfo
- Publication number
- SG11202101905YA SG11202101905YA SG11202101905YA SG11202101905YA SG11202101905YA SG 11202101905Y A SG11202101905Y A SG 11202101905YA SG 11202101905Y A SG11202101905Y A SG 11202101905YA SG 11202101905Y A SG11202101905Y A SG 11202101905YA SG 11202101905Y A SG11202101905Y A SG 11202101905YA
- Authority
- SG
- Singapore
- Prior art keywords
- vitamin
- making
- methods
- dosage forms
- pediatric dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725940P | 2018-08-31 | 2018-08-31 | |
| PCT/IB2019/057360 WO2020044314A1 (en) | 2018-08-31 | 2019-08-30 | Vitamin d pediatric dosage forms, methods of making and using |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202101905YA true SG11202101905YA (en) | 2021-03-30 |
Family
ID=68165642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202101905YA SG11202101905YA (en) | 2018-08-31 | 2019-08-30 | Vitamin d pediatric dosage forms, methods of making and using |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11000480B2 (en) |
| EP (1) | EP3843706A1 (en) |
| JP (1) | JP2021535155A (en) |
| KR (1) | KR20210054539A (en) |
| CN (1) | CN112912067A (en) |
| AU (3) | AU2019329905B2 (en) |
| BR (1) | BR112021003788A2 (en) |
| CA (1) | CA3110020A1 (en) |
| CL (2) | CL2021000493A1 (en) |
| CO (1) | CO2021003805A2 (en) |
| CR (1) | CR20210158A (en) |
| DE (1) | DE202019005769U1 (en) |
| EA (1) | EA202190633A1 (en) |
| EC (1) | ECSP21021189A (en) |
| IL (1) | IL280937A (en) |
| MX (1) | MX2020011740A (en) |
| PE (1) | PE20211489A1 (en) |
| PH (1) | PH12021550413A1 (en) |
| SG (1) | SG11202101905YA (en) |
| TW (1) | TW202034905A (en) |
| WO (1) | WO2020044314A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220164539A (en) | 2020-04-06 | 2022-12-13 | 에어젠 파마 엘티디. | 25-hydroxyvitamin D for the treatment of SARS-CoV-2 infection |
| CA3181945A1 (en) | 2020-05-31 | 2021-12-09 | Eirgen Pharma Ltd. | Hard capsule dosage form and uses thereof |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| CN114176164A (en) * | 2021-12-17 | 2022-03-15 | 广东驱动力生物科技股份有限公司 | Water-soluble anti-stress additive for ruminants |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59155309A (en) * | 1983-02-22 | 1984-09-04 | Teijin Ltd | Active type vitamin d3 composition and its preparation |
| ES2094290T3 (en) * | 1991-04-09 | 1997-01-16 | Takeda Chemical Industries Ltd | STABILIZED PREPARATION OF VITAMIN D. |
| ATE211387T1 (en) * | 1992-06-22 | 2002-01-15 | Bone Care Int Inc | ORAL 1ALPHA-HYDROXYPREVITAMIN D |
| US7632518B2 (en) * | 2002-01-15 | 2009-12-15 | Dsm Ip Assets B.V. | 25-hydroxy vitamin D3 compositions |
| SI3095447T1 (en) * | 2006-02-03 | 2022-02-28 | Opko Renal, Llc | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
| PL2148661T3 (en) | 2007-04-25 | 2013-07-31 | Cytochroma Inc | Oral controlled release compositions comprising vitamin d compound and waxy carrier |
| CN101584683A (en) * | 2009-06-12 | 2009-11-25 | 沈阳药科大学 | Metolazone slow-release capsule and method for preparing same |
| WO2012047098A1 (en) * | 2010-10-04 | 2012-04-12 | Dishman Pharmaceuticals And Chemicals Ltd. | Encapsulated fat-soluble vitamin |
| US9907758B2 (en) * | 2012-01-09 | 2018-03-06 | Panjab University Department Of Biotechnology (Dbt) | Process for preparing solid lipid sustained release nanoparticles for delivery of vitamins |
| KR101847947B1 (en) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | Stabilized modified release vitamin d formulation |
| US20160008377A1 (en) * | 2014-07-12 | 2016-01-14 | Aphios Corporation | Formulations and compositions of vitamin d analogs for treating and preventing cancer and other diseases |
| CN114681468A (en) * | 2014-08-07 | 2022-07-01 | 欧普科爱尔兰环球控股有限公司 | Adjunctive therapy with 25-hydroxyvitamin D |
| CN108420797B (en) * | 2018-05-09 | 2022-05-03 | 南京海融制药有限公司 | Vitamin D analogue preparation and preparation method thereof |
-
2019
- 2019-08-30 SG SG11202101905YA patent/SG11202101905YA/en unknown
- 2019-08-30 PE PE2021000260A patent/PE20211489A1/en unknown
- 2019-08-30 EP EP19783665.3A patent/EP3843706A1/en active Pending
- 2019-08-30 WO PCT/IB2019/057360 patent/WO2020044314A1/en active Application Filing
- 2019-08-30 EA EA202190633A patent/EA202190633A1/en unknown
- 2019-08-30 BR BR112021003788-8A patent/BR112021003788A2/en unknown
- 2019-08-30 KR KR1020217009143A patent/KR20210054539A/en active Search and Examination
- 2019-08-30 JP JP2021510876A patent/JP2021535155A/en active Pending
- 2019-08-30 CN CN201980064183.4A patent/CN112912067A/en active Pending
- 2019-08-30 MX MX2020011740A patent/MX2020011740A/en unknown
- 2019-08-30 DE DE202019005769.2U patent/DE202019005769U1/en active Active
- 2019-08-30 CR CR20210158A patent/CR20210158A/en unknown
- 2019-08-30 TW TW108131446A patent/TW202034905A/en unknown
- 2019-08-30 CA CA3110020A patent/CA3110020A1/en active Pending
- 2019-08-30 AU AU2019329905A patent/AU2019329905B2/en active Active
-
2020
- 2020-05-07 US US16/869,273 patent/US11000480B2/en active Active
-
2021
- 2021-02-17 IL IL280937A patent/IL280937A/en unknown
- 2021-02-26 CL CL2021000493A patent/CL2021000493A1/en unknown
- 2021-02-26 PH PH12021550413A patent/PH12021550413A1/en unknown
- 2021-03-25 CO CONC2021/0003805A patent/CO2021003805A2/en unknown
- 2021-03-26 EC ECSENADI202121189A patent/ECSP21021189A/en unknown
- 2021-04-07 US US17/224,768 patent/US20210401752A1/en active Pending
- 2021-08-25 AU AU2021107174A patent/AU2021107174A4/en active Active
- 2021-08-25 AU AU2021107168A patent/AU2021107168A4/en active Active
- 2021-09-17 US US17/478,395 patent/US20220000783A1/en active Pending
-
2023
- 2023-08-28 CL CL2023002539A patent/CL2023002539A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020011740A (en) | 2021-04-19 |
| AU2021107174A4 (en) | 2021-12-09 |
| IL280937A (en) | 2021-04-29 |
| JP2021535155A (en) | 2021-12-16 |
| AU2021107168A4 (en) | 2021-12-09 |
| EP3843706A1 (en) | 2021-07-07 |
| US11000480B2 (en) | 2021-05-11 |
| US20220000783A1 (en) | 2022-01-06 |
| CA3110020A1 (en) | 2020-03-05 |
| DE202019005769U1 (en) | 2022-01-13 |
| PH12021550413A1 (en) | 2021-09-27 |
| PE20211489A1 (en) | 2021-08-11 |
| CR20210158A (en) | 2021-05-21 |
| US20200338006A1 (en) | 2020-10-29 |
| ECSP21021189A (en) | 2021-04-29 |
| US20210401752A1 (en) | 2021-12-30 |
| BR112021003788A2 (en) | 2021-06-08 |
| CL2021000493A1 (en) | 2021-07-23 |
| AU2019329905B2 (en) | 2024-02-01 |
| WO2020044314A1 (en) | 2020-03-05 |
| KR20210054539A (en) | 2021-05-13 |
| CN112912067A (en) | 2021-06-04 |
| CO2021003805A2 (en) | 2021-04-19 |
| CL2023002539A1 (en) | 2024-02-23 |
| EA202190633A1 (en) | 2021-07-12 |
| AU2019329905A1 (en) | 2021-03-18 |
| TW202034905A (en) | 2020-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273706A (en) | Liquid dosage forms, methods of making and use | |
| HUE054964T2 (en) | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | |
| EP3681479A4 (en) | Method of administration and treatment | |
| HK1255566A1 (en) | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof | |
| IL259711A (en) | Protein kinase inhibitor, preparation method and medical use thereof | |
| IL280937A (en) | Vitamin d pediatric dosage forms, methods of making and using | |
| GB201817116D0 (en) | Pharmaceutical preparation of palbociclic and preparation method thereof | |
| HK1254642A1 (en) | Devices and methods for drug administration and mixing, and training of proper techniques therefor | |
| PT3487505T (en) | Administration and dosage of diaminophenothiazines | |
| IL272446A (en) | Substituted penta- fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | |
| EP3307381A4 (en) | Multivector patient electrode system and method of use | |
| EP3347348A4 (en) | Preparation of 3-hydroxy-3,6-dimethylhexahydrobenzofuran-2-one and derivatives thereof | |
| EP3653202A4 (en) | Pharmaceutical preparation and preparation method therefor | |
| EP3115377A4 (en) | Mutant antibody of full human her2 antibody, coding gene and use thereof | |
| ZA201906326B (en) | Analogs of deutetrabenazine, their preparation and use | |
| HK1223630A1 (en) | Dosage and administration anti-egfr therapeutics -egfr | |
| GB201812324D0 (en) | Near-infraed chromophores, process of preparation and methods of use | |
| EP3437681A4 (en) | Medicine administering apparatus, method of using medicine administering apparatus, and method for manufacturing medicine administering apparatus | |
| EP3425388A4 (en) | Method for assessing pain caused by administration of drug solution, and method for selecting drug solution administration | |
| IL271727A (en) | Method of treatment and dosage forms thereof | |
| IL291196A (en) | Drug dosage determination devices and methods | |
| EP3664831A4 (en) | Anti-neurodegenerative therapeutic, method of manufacture, and use | |
| GB201710382D0 (en) | Administration and dosage of Diaminophenothiazines | |
| HK1259196A1 (en) | Delayed-release formulations, methods of making and use thereof | |
| AU2017904756A0 (en) | Pharmaceutical combinations and methods of treatment |